Revolution Medicines: The Attack on the Unbreakable Cancer Code

Revolution Medicines develops novel compounds that specifically block the active form of cancer-causing RAS proteins, which have previously been considered untreatable and account for about one-third of all cancer cases. With the advanced candidate Daraxonrasib, the company is addressing a significant supply gap in difficult-to-treat tumors such as pancreatic and lung cancer. Thanks to strong capital partners, the transition from research to commercial provider is financially secured; however, the stock remains a speculative biotech title...